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Celecoxib (Celebrex
s) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain.
However, it now appears that this compound harbours additional pharmacologic activities that are entirely independent of its COX-
2-inhibitory activity. This review presents the recently emerged direct non-COX-2 targets of celecoxib and their proposed role in
mediating this drug’s antitumour effects.
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Although celecoxib (Celebrex) was developed as a selective
cyclooxygenase-2 (COX-2) inhibitor, additional pharmacologic
activities have emerged outside of its analgesic activity. For
instance, its potency to inhibit COX-2 in the nanomolar range has
been eclipsed by its ability to inhibit various isoforms of carbonic
anhydrase (CA) at even lower concentrations (see below). More-
over, when added to cells in culture at moderate micromolar
concentrations, celecoxib was shown to affect several additional
cellular components with roles in cellular proliferation and
survival (Gro ¨sch et al, 2006).
When employed in the micromolar range in cell culture, the
molecular mechanism by which celecoxib exerts its myriad of
pharmacologic activities has not been fully elucidated. But among
the various targets, there are at least two cellular components that
seem to be controlled directly by celecoxib and thus appear to
represent receptors that are engaged at moderate micromolar
concentrations. One of these is 3-phosphoinositide-dependent
protein kinase-1 (PDK1) and the other is sarcoplasmic/endo-
plasmic reticulum (ER) calcium ATPase (SERCA). When studied
in vitro, inhibition of both PDK1 and SERCA requires substantially
higher drug concentrations than are necessary to inhibit either
COX-2 or CAs; nonetheless, recent evidence obtained from the use
of animal tumour models demonstrates that PDK-1 and SERCA are
also affected by celecoxib in vivo (see below). Therefore, these non-
COX-2 targets of celecoxib should be taken into account when
interpreting experimental results obtained from the use of
celecoxib.
The above findings indicate that the ‘selective’ inhibitor
celecoxib has lost its selectivity over time, simply due to the
discovery of additional drug targets. This poses the obvious
dilemma that observed drug effects cannot be easily ascribed solely
to the inhibition of COX-2, but must be supported by careful
controls in order to establish the relevant mechanism of drug action.
In other words, even though inhibition of COX-2 may take place,
this observation by itself does not establish this particular
pharmacologic activity as the underlying mechanism by which
celecoxib exerts its antitumour properties. For instance, if certain
phenotypic consequences observed with celecoxib were attributed to
the inhibition of COX-2 activity alone, one would expect that
other COX-2 inhibitors, such as rofecoxib (Vioxx
s), valdecoxib
(Bextra
s) or those traditional non-steroidal anti-inflammatory
drugs (NSAIDs) that inhibit both COX-1 and COX-2, should
also demonstrate these types of biological activities. This is clearly
the case in many inflammatory conditions, where the activities seen
with NSAIDs can be attributed to COX-2 inhibition. In addition,
chemoprevention of colon cancer is also an established pharmaco-
logic activity where inhibition of COX-2 correlates with the
suppression of tumour development (Koehne and Dubois, 2004).
In contrast to the foregoing, the antitumour activities of
celecoxib in advanced cancers are not well delineated (Kashfi
and Rigas, 2005). On one hand, there is clear evidence that COX-2
is an important player even in advanced tumours, where a
constellation of other cellular components, such as activated
oncogenes and inactivated tumour suppressors, has usurped
growth control and drives the malignant expansion. On the other
hand, there are an increasing number of reports indicating that
celecoxib does not require the presence of COX-2 in order to exert
its antitumour activities (Kashfi and Rigas, 2005; Gro ¨sch et al,
2006; Scho ¨nthal, 2007). Even more striking, it was demonstrated
that close structural analogues of celecoxib – devoid of any COX-2
inhibitory activity – were able to potently mimic all antitumour
properties of celecoxib investigated so far, not just in vitro but also
in various xenograft animal tumour models in vivo (Song et al,
2002; Kulp et al, 2004; Scho ¨nthal, 2006). In the absence of COX-2
inhibition, the recently emerged non-COX-2 receptors and targets
of celecoxib are obvious candidates to mediate these antitumour
effects in advanced cancers.
The following summary will primarily focus on those non-COX-
2 targets of celecoxib that are able to directly bind to the drug and
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Owing to space restrictions, other established COX-2-independent
targets of celecoxib will not be discussed in greater detail (Kashfi
and Rigas, 2005; Gro ¨sch et al, 2006). Moreover, the very large body
of literature establishing and supporting a central role for COX-2
in the actions of celecoxib will not be presented here; the interested
reader is referred to some of the excellent recent reviews in that
area (Fu ¨rstenberger et al, 2006).
CARBONIC ANHYDRASES AS TARGETS FOR
CELECOXIB
More than a dozen different isoforms of CA are known. They are
zinc metalloenzymes that catalyse the reversible interconversion of
carbon dioxide and bicarbonate and thereby regulate physiological
pH and other processes. At least two of them, CAs IX and XII
(CAIX and CAXII), are expressed in a wide variety of malignancies
and implicated in tumour growth (see details in reference
Pastorekova et al, 2007). CAIX in particular is linked to poor
prognosis in a number of human tumours. Its pronounced
induction under hypoxia is thought to support tumour cell growth
under such adverse conditions and might contribute to resistance
against cytotoxic chemotherapy (Potter and Harris, 2003).
Further evidence of the importance of certain CAs in the
oncogenic process comes from investigations of clinically relevant
CA inhibitors, most notably, the heterocyclic and aromatic
sulphonamides, such as acetazolamide, methazolamide or ethox-
zolamide, which are normally used for glaucoma and other
medical purposes. Several of these CA inhibitors have demon-
strated pronounced antitumour effects in various in vitro and
in vivo models (Supuran et al, 2003).
Celecoxib, like the prototype CA inhibitor acetazolamide, is
structurally characterised by an unsubstituted sulphonamide
moiety (Figure 1). Despite this telling chemical similarity, it came
as a surprise when it was discovered that celecoxib displayed
potent CA inhibitory activity in the low nanomolar range in vitro
(Knudsen et al, 2004; Weber et al, 2004). In fact, its IC50 towards
the tumour-associated CAIX and CAXII enzymes was determined
to be 16 and 18nM, respectively (Di Fiore et al, 2006), and thus was
more than double as potent than its inhibition of COX-2, where the
IC50 is 40nM (Penning et al, 1997). Similarly, valdecoxib, a
sulphonamide-based coxib as well (Figure 1), was able to inhibit
CAIX and CAXII with comparable potency, although its binding
mode was entirely different from celecoxib (Di Fiore et al, 2006).
In contrast, several non-sulphonamide COX inhibitors tested,
including rofecoxib, a methylsulphone-type coxib (Figure 1), had
no CA inhibitory activity (Knudsen et al, 2004; Weber et al, 2004).
The ability of celecoxib and valdecoxib to inhibit CAs in vivo was
confirmed in glaucomatous rabbits, where both drugs were able to
lower intraocular pressure, suggesting that these agents may have
utility in the treatment of this disorder (Weber et al, 2004).
The proposed role of CAIX and CAXII in tumour proliferation,
progression and chemoresistance begs the question as to whether
these enzymes might represent potentially crucial players in the
antitumour mechanisms of celecoxib. Unfortunately, at present,
there are no data available to support such an assessment.
PDK1 AS A TARGET FOR CELECOXIB
Much excitement was generated by the finding that celecoxib could
bind to and inhibit PDK1 (Arico et al, 2002; Kulp et al, 2004).
PDK1 is a crucial component of cell growth and survival signalling
pathways that also involve its upstream regulator PI3K (phospha-
titylinositol-3-kinase), its major downstream substrate Akt/PKB
(protein kinase B) and the tumour suppressor PTEN (phosphatase
and tensin homologue deleted on chromosome 10), which acts as a
negative regulator of PI3K/PDK1/Akt signalling. In many tumour
cells, especially in those with deleted PTEN, the PI3K/PDK1/Akt
axis is chronically activated and contributes to tumour growth and
chemoresistance. Considering the master regulatory role of PDK1
in pro-oncogenic pathways, the discovery of its inhibition by
celecoxib provided a suitable explanation for the drug’s COX-2-
independent antitumour effects (Hsu et al, 2000; Kulp et al, 2004).
In comparison to COX-2 or CA inhibition, significantly higher
concentrations of celecoxib are required to inhibit the enzymatic
activity of PDK1 in vitro, and IC50s from 3.5mM (Arico et al, 2002)
to 48mM were reported (Kulp et al, 2004). The latter value is more
in line with the growth-inhibitory and apoptosis-inducing
potential of celecoxib in cell culture, where generally concentra-
tions in the range of 30–100mM are needed to exert pronounced
antiproliferative effects.
Despite several lines of evidence that PDK1 could be a major COX-
2-independent receptor of celecoxib, further studies raised some
concerns as to the general validity of this model. For instance, in our
own studies, we did not detect substantial celecoxib-mediated
inhibition of PDK1 (Kardosh et al, 2005). Furthermore, celecoxib
induced apoptosis with equal efficacy in mouse embryonic
fibroblasts lacking both PDK1 alleles as compared to their wild-
type counterparts that expressed PDK1 normally (Kardosh et al,
2005). Moreover, the downregulation of phosphorylation of the
primary PDK1 target Akt, which has been reported in several
celecoxib-treated tumour cell lines (Hsu et al, 2000; Arico et al,2 0 0 2 ;
Song et al,2 0 0 2 ;K u l pet al, 2004), is not consistently observed in all
tumour cells (Kern et al, 2002; Kardosh et al, 2005), even though
apoptosis is similarly induced by drug treatment.
Although questions remain as to the precise role of PDK1 in
celecoxib-induced antitumour processes, the recognition of PDK1
as a target of celecoxib prompted subsequent structure-activity
analysis combined with molecular modelling to generate COX-2
inactive celecoxib derivatives with increased potency towards
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the key role of PDK1 in tumour growth, such streamlined
compounds are expected to be useful in cancer therapy.
SERCA AS A TARGET FOR CELECOXIB
The discovery (Johnson et al, 2002) that celecoxib is able to inhibit
the sarcoplasmic/ER calcium ATPase (SERCA) set the stage for
subsequent studies that eventually established the ER stress
response (ESR) as a crucial non-COX-2 target of celecoxib. SERCA
is a transmembrane ER protein that maintains the steep gradient
of calcium between the cytosol and the ER. Many studies with
thapsigargin, a widely used model inhibitor of SERCA, have
established that inhibition of this pump results in rapid leakage of
calcium into the cytosol; as a result, the ESR is triggered. The
primary purpose of the ESR is to alleviate the respective stressful
disturbance and restore proper ER homeostasis; however, in the
case of intense or persistent ER stress, as appears to be the case in
the continued presence of celecoxib, this mechanism will trigger
programmed cell death/apoptosis.
A number of papers (Johnson et al, 2002; Tanaka et al, 2005;
Alloza et al, 2006; Pyrko et al, 2007a) have demonstrated that
calcium release from the ER is the most immediate effect of
celecoxib treatment and can be detected within seconds of adding
the drug to cells in culture. As a consequence, and very similar to
what has been established for the model inducer thapsigargin, the
typical features of severe ESR can be observed (Tsutsumi et al,
2004, 2006; Kim et al, 2007; Pyrko et al, 2007a). Among these
features is the phosphorylation and inactivation of translation
initiation factor 2a (eIF2a), which causes a prominent, yet
transient, shutdown of general protein synthesis (Pyrko et al,
2007a,b). Exempt from this inhibition of general translation are
ESR-specific proteins, such as the chaperone protein GRP78
(glucose-regulated protein with molecular weight 78kDa) or
CHOP/GADD153 (CCAAT/enhancer binding protein homologous
transcription factor), an important transcription factor that is
involved in mediating ESR-induced apoptosis. Both of these
proteins are strongly induced by celecoxib (Tsutsumi et al, 2004,
2006; Pyrko et al, 2007a,b).
The substantial ESR-mediated downregulation of general
translation by celecoxib might have considerable implications for
the interpretation of some of the other reported COX-2-
independent effects of this drug. For example, celecoxib treatment
of cells in culture has been shown to result in cell cycle arrest
(Gro ¨sch et al, 2001; Kardosh et al, 2004). This appears to be due to
the downregulation of various cyclin proteins, which are the
essential subunits of cyclin-dependent kinases (CDKs) that
constitute the cell cycle engine and drives the cells through the
cell cycle. Loss of CDK activity prevents the phosphorylation of
CDK target proteins, most prominent among them the retino-
blastoma (Rb) tumour suppressor protein, which remains
hypophosphorylated and thus enforces the restriction point and
concomitant growth arrest in G1. It is quite tempting to conjecture
that all of these known effects of celecoxib, that is, downregulation
of cyclins, inhibition of CDK activity, loss of Rb phosphorylation,
and ensuing cell cycle arrest could result from the drug’s inhibition
of SERCA: inhibition of this pump generates increased cytosolic
calcium levels, which trigger severe ER stress and attenuate general
protein synthesis; as a consequence, short-lived proteins, such as
cyclin D, disappear quickly and cannot be replenished. Without
cyclin D, the essential G1 CDKs become inactive and incapable of
phosphorylating their major substrate Rb protein; as a result,
hypophosphorylated Rb remains active and prevents cells from
progressing towards S phase. Thus, in this scenario, the effects of
celecoxib on SERCA and ER stress would suffice to explain its
seemingly unrelated effects on the cell cycle machinery.
Activation of the ESR has also been detected in tumour tissue
from celecoxib-treated animals, clearly demonstrating that these in
vitro effects of the drug also take place in vivo (Tsutsumi et al,
2004; Pyrko et al, 2007a). This latter observation is particularly
important in view of earlier scepticism as to the relevance of in
vitro findings with celecoxib (Williams et al, 2000). As many COX-
2-independent effects of celecoxib, including the stimulation of
ESR, only take place at elevated concentrations, that is in the range
of 10–100mM in vitro, it was questioned whether these results
might have relevance in vivo, where drug concentrations generally
are below 5mM. The detection of ER stress in tumour tissue from
celecoxib-treated animals clearly indicated that the in vitro
observations have in vivo relevance – although the conundrum
of the concentration differential between in vitro and in vivo
conditions remains, and the potential role of additional, still
unknown targets of celecoxib cannot be excluded.
Intriguingly, ESR-inducing activity is also displayed by 2,5-
dimethyl-celecoxib (DMC) (Pyrko et al, 2007a), a well-studied
structural analogue of celecoxib that lacks COX-2 inhibitory
function (Figure 1). In fact, DMC has been shown to faithfully
mimic – at increased potency – each and every one of celecoxib’s
non-COX-2 effects investigated so far in vitro and in vivo (Kulp
et al, 2004; Scho ¨nthal, 2006), further substantiating the presence of
multiple activities within the celecoxib molecule.
CONCLUSIONS
Celecoxib is unique among the coxibs and traditional NSAIDs,
because this particular drug displays the greatest potency to induce
apoptotic cell death. This activity does not correlate with the
inhibition of COX-2, but is congruent with its unique ability to
inhibit the non-COX-2 targets PDK1 and SERCA at moderate
micromolar concentrations. The inhibition of SERCA constitutes a
very rapid drug effect, as increased concentrations of cytosolic
calcium levels can be measured within seconds after the addition
of celecoxib to intact cells. Significantly, inhibition of these non-
COX-2 targets by celecoxib also seems to occur in animal tumour
models in vivo, arguing against earlier concerns that such effects
might be artefacts of the high drug concentrations used in cell
culture systems in vitro. Additionally, celecoxib is able to inhibit
the tumour-associated CAs IX and XII at nanomolar concentra-
tions that are below those required for inhibition of its original
target, COX-2.
Although it shall remain undisputed that the inhibition of COX-2,
as exerted by celecoxib, has clinically relevant antineoplastic
applications, it is also apparent that the celecoxib molecule harbours
additional activities that may exert antitumour functions indepen-
dent of the COX-2 inhibitory activity. It is therefore important to
consider the entirety of these multifaceted effects when interpreting
data obtained from the experimental use of celecoxib.
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